Clinical Trial: Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07874282) titled 'Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer' on Sept. 30.

Brief Summary: To Evaluate the Safety, Tolerability, and Preliminary Antitumor Efficacy of RC148 in Combination with Telisotuzumab adizutecan as First-line Treatment for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cy...